相似文献
1
Pharmacogenomics--how close/far are we to practising individualized medicine for children?
Br J Clin Pharmacol. 2015 Mar;79(3):419-28. doi: 10.1111/bcp.12338.
2
Pharmacogenomics and individualized medicine: translating science into practice.
Clin Pharmacol Ther. 2012 Oct;92(4):467-75. doi: 10.1038/clpt.2012.120. Epub 2012 Sep 5.
3
Personalized Medicine in the Paediatric Population: The Balance Between Pharmacogenetic Progress and Bioethics.
Curr Pharm Biotechnol. 2017;18(3):253-262. doi: 10.2174/1389201018666170207130236.
4
Pharmacogenomics: personalizing pediatric heart transplantation.
Circulation. 2015 Feb 3;131(5):503-12. doi: 10.1161/CIRCULATIONAHA.114.001382.
5
Pharmacogenomics in Critical Care.
AACN Adv Crit Care. 2018 Spring;29(1):36-42. doi: 10.4037/aacnacc2018398.
6
Pharmacogenomics in pediatrics: personalized medicine showing eminent promise.
J Pediatr Nurs. 2014 Jul-Aug;29(4):378-82. doi: 10.1016/j.pedn.2014.04.005. Epub 2014 May 10.
7
Pharmacogenetics, pharmacogenomics, and individualized medicine.
Pharmacol Rev. 2011 Jun;63(2):437-59. doi: 10.1124/pr.110.003533. Epub 2011 Mar 24.
8
PACE Forward-Making Pharmacogenomics Testing Available for Real-Life Clinical Utility.
Clin Pharmacol Ther. 2019 Jan;105(1):42-44. doi: 10.1002/cpt.1274. Epub 2018 Dec 5.
9
"Pharmacogenomics: achievements, challenges and prospects, for patients, pharmaceutical industries and healthcare systems".
Curr Pharm Des. 2010;16(20):2182-3. doi: 10.2174/138161210791792840.
10
Conference scene: pediatric pharmacogenomics and personalized medicine.
Pharmacogenomics. 2010 Dec;11(12):1691-702. doi: 10.2217/pgs.10.175.
引用本文的文献
1
Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis.
Front Pharmacol. 2025 Jul 16;16:1568320. doi: 10.3389/fphar.2025.1568320. eCollection 2025.
2
Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland.
Pharmacogenomics J. 2025 Jul 11;25(4):19. doi: 10.1038/s41397-025-00378-x.
3
Translating Precision Health for Pediatrics: A Scoping Review.
Children (Basel). 2023 May 17;10(5):897. doi: 10.3390/children10050897.
4
Practice of CYP450 genotyping and phenotyping in children in a real-life setting.
Front Pharmacol. 2023 Feb 27;14:1130100. doi: 10.3389/fphar.2023.1130100. eCollection 2023.
5
Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
JAMA Netw Open. 2021 May 3;4(5):e2110446. doi: 10.1001/jamanetworkopen.2021.10446.
6
Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges.
Pharmgenomics Pers Med. 2019 Oct 14;12:273-285. doi: 10.2147/PGPM.S179172. eCollection 2019.
7
Implementation and obstacles of pharmacogenetics in clinical practice: An international survey.
Br J Clin Pharmacol. 2019 Sep;85(9):2076-2088. doi: 10.1111/bcp.13999. Epub 2019 Jul 7.
8
Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.
Clin Transl Sci. 2019 Mar;12(2):172-179. doi: 10.1111/cts.12589. Epub 2018 Oct 20.
9
Genome sequencing as a platform for pharmacogenetic genotyping: a pediatric cohort study.
NPJ Genom Med. 2017 May 26;2:19. doi: 10.1038/s41525-017-0021-8. eCollection 2017.
10
[Treat to target and personalized medicine (precision medicine)].
Z Rheumatol. 2016 Aug;75(6):624-32. doi: 10.1007/s00393-016-0137-8.
本文引用的文献
1
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
Clin Pharmacol Ther. 2013 Aug;94(2):252-9. doi: 10.1038/clpt.2013.121. Epub 2013 Jun 11.
2
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.
Clin Pharmacol Ther. 2013 Aug;94(2):243-51. doi: 10.1038/clpt.2013.80. Epub 2013 Apr 10.
3
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update.
Clin Pharmacol Ther. 2013 Apr;93(4):324-5. doi: 10.1038/clpt.2013.4. Epub 2013 Jan 17.
4
CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.
J Clin Psychiatry. 2012 Sep;73(9):1187-90. doi: 10.4088/JCP.11m07572.
5
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record.
Clin Pharmacol Ther. 2012 Nov;92(5):563-6. doi: 10.1038/clpt.2012.140. Epub 2012 Sep 19.
6
Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?
Pharmacogenomics. 2012 Aug;13(11):1211-4. doi: 10.2217/pgs.12.92.
7
A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).
Circulation. 2012 Apr 24;125(16):1997-2005. doi: 10.1161/CIRCULATIONAHA.111.070920. Epub 2012 Mar 19.
8
VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
Blood. 2012 Jan 19;119(3):868-73. doi: 10.1182/blood-2011-08-372722. Epub 2011 Oct 18.
9
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
Clin Pharmacol Ther. 2011 Oct;90(4):625-9. doi: 10.1038/clpt.2011.185. Epub 2011 Sep 7.
10
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
J Clin Oncol. 2012 May 1;30(13):1422-8. doi: 10.1200/JCO.2010.34.3467. Epub 2011 Sep 6.
Zotero 插件